PR
ProQR Therapeutics N.V.
PRQR · NASDAQ
$1.83 -3.17% (-$0.06)
1M -24.69%
Market Cap 167.8M €
P/E Ratio -
Div. Yield -
ROE 68.44%
Piotroski F-Score Weak
1/9Valuation
43 /100
Fair P/S 9.04x
P/B 2.11x
P/E N/A
Growth
78 /100
Growing Rev. growth 61.99%
Book val. growth 9.72%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 92.33%
FCF margin 270.78%
Net margin 228.29%
Quality
2 /100
Poor ROIC 41.93%
Asset turnover 0.14x
ROE 68.44%
Debt
100 /100
Low Debt/Equity 0.17x
Current ratio 3.49x
Int. coverage N/A
Stability
16 /100
Unstable Beta 0.03x
Profitable years 0
Rev. volatility 104.73%
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na PRQR
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Daniel Anton de Boer
Employees
166
Headquarters
Leiden
Nadcházející události
05 LIS
Earnings
Upcoming earnings report